{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:49:22Z","timestamp":1740160162303,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014088","name":"AstraZeneca, France.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s13300-017-0311-2","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T08:34:25Z","timestamp":1506328465000},"page":"1147-1162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2021-413X","authenticated-orcid":false,"given":"Beverley","family":"Balkau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Charbonnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Penfornis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Chraibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Lahouegue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Faure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Thomas-Delecourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Detournay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"311_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 7th ed. 2015. http:\/\/www.diabetesatlas.org\/across-the-globe.html . Accessed 27 Aug 2017."},{"key":"311_CR2","unstructured":"Donn\u00e9es \u00e9pid\u00e9miologiques. Pr\u00e9valence et incidence du diab\u00e8te. http:\/\/invs.santepubliquefrance.fr\/Dossiers-thematiques\/Maladies-chroniques-et-traumatismes\/Diabete . Accessed 27 Aug 2017."},{"key":"311_CR3","unstructured":"Fosse-Edorh S, Mandereau-Bruno L, Regnault N. The burden of diabetes-related complications in France in 2013. Summary and perspectives. Bull Epid\u00e9miol Hebd. 2015;34\u201335:619\u201325. http:\/\/invs.santepubliquefrance.fr\/beh\/2015\/34-35\/pdf\/2015_34-35_1.pdf . Accessed 27 Aug 2017."},{"key":"311_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.12591","volume":"18","author":"M Nauck","year":"2016","unstructured":"Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18:203\u201316.","journal-title":"Diabetes Obes Metab"},{"key":"311_CR5","doi-asserted-by":"publisher","first-page":"E1223","DOI":"10.3390\/ijms17081223","volume":"17","author":"D Kawanami","year":"2016","unstructured":"Kawanami D, Matoba K, Sango K, Utsunomiya K. Incretin-based therapies for diabetic complications: basic mechanisms and clinical evidence. Int J Mol Sci. 2016;17:E1223.","journal-title":"Int J Mol Sci"},{"key":"311_CR6","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.2337\/db14-0052","volume":"63","author":"B Omar","year":"2014","unstructured":"Omar B, Ahr\u00e9n B. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes. 2014;63:2196\u2013202.","journal-title":"Diabetes"},{"key":"311_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s13300-017-0261-8","volume":"8","author":"M Sj\u00f6strand","year":"2017","unstructured":"Sj\u00f6strand M, Wei C, Cook W, et al. Assessment of saxagliptin efficacy: meta-analysis of 14 phase 2 and 3 clinical trials. Diabetes Ther. 2017;8:587\u201399.","journal-title":"Diabetes Ther."},{"issue":"1 Suppl","key":"311_CR8","doi-asserted-by":"publisher","first-page":"19S","DOI":"10.1177\/0145721715609420","volume":"41","author":"D Hinnen","year":"2015","unstructured":"Hinnen D. Dipeptidyl peptidase-4 inhibitors in diverse patient populations with type 2 diabetes. Diabetes Educ. 2015;41(1 Suppl):19S\u201331S.","journal-title":"Diabetes Educ."},{"key":"311_CR9","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s40265-015-0473-z","volume":"75","author":"S Dhillon","year":"2015","unstructured":"Dhillon S. Saxagliptin: a review in type 2 diabetes. Drugs. 2015;75:1783\u201396.","journal-title":"Drugs."},{"issue":"Suppl 1","key":"311_CR10","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1517\/14740338.2014.944862","volume":"13","author":"A Ceriello","year":"2014","unstructured":"Ceriello A, Sportiello L, Rafaniello C, Rossi F. DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin Drug Saf. 2014;13(Suppl 1):S57\u201368.","journal-title":"Expert Opin Drug Saf."},{"key":"311_CR11","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/1440-1681.12455","volume":"42","author":"XW Chen","year":"2015","unstructured":"Chen XW, He ZX, Zhou ZW, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42:999\u20131024.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"311_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2210-12-2","volume":"12","author":"A Wang","year":"2012","unstructured":"Wang A, Dorso C, Kopcho L, et al. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol. 2012;12:2.","journal-title":"BMC Pharmacol"},{"key":"311_CR13","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1185\/03007990903178735","volume":"25","author":"J Rosenstock","year":"2009","unstructured":"Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-na\u00efve patients with type 2 diabetes. Curr Med Res Opin. 2009;25:2401\u201311.","journal-title":"Curr Med Res Opin"},{"key":"311_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1463-1326.2009.01056.x","volume":"11","author":"M Jadzinsky","year":"2009","unstructured":"Jadzinsky M, Pf\u00fctzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611\u201322.","journal-title":"Diabetes Obes Metab"},{"key":"311_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2337\/dc08-1984","volume":"32","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649\u201355.","journal-title":"Diabetes Care"},{"key":"311_CR16","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/j.1742-1241.2010.02510.x","volume":"64","author":"B G\u00f6ke","year":"2010","unstructured":"G\u00f6ke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I, D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64:1619\u201331.","journal-title":"Int J Clin Pract"},{"key":"311_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/dmrr.1114","volume":"26","author":"AJ Scheen","year":"2010","unstructured":"Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540\u20139.","journal-title":"Diabetes Metab Res Rev."},{"key":"311_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/j.1742-1241.2009.02143.x","volume":"63","author":"AR Chacra","year":"2009","unstructured":"Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R, CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63:1395\u2013406.","journal-title":"Int J Clin Pract"},{"key":"311_CR19","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1210\/jc.2009-0550","volume":"94","author":"P Hollander","year":"2009","unstructured":"Hollander P, Li J, Allen E, Chen R, CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"311_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/dom.12234","volume":"16","author":"RG Moses","year":"2014","unstructured":"Moses RG, Kalra S, Brook D, et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab. 2014;16:443\u201350.","journal-title":"Diabetes Obes Metab"},{"key":"311_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1185\/03007995.2012.665046","volume":"28","author":"AH Barnett","year":"2012","unstructured":"Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28:513\u201323.","journal-title":"Curr Med Res Opin"},{"key":"311_CR22","unstructured":"Onglyza Summary of Product Characteristics. http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h545.htm . Accessed 27 Aug 2017."},{"key":"311_CR23","unstructured":"Komboglyze Summary of Product Characteristics. http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h731.htm . Accessed 27 Aug 2017."},{"key":"311_CR24","unstructured":"AFSSAPS - HAS. Type 2 diabetes treatment: French recommendations for good practice AFSSAPS\u2014HAS.2006. Diabetes Metab. 2006;32:643\u20138."},{"key":"311_CR25","unstructured":"Caisse nationale de l\u2019Assurance Maladie des travailleurs salari\u00e9s (CNAMTS). Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et ma\u00eetriser les d\u00e9penses. Propositions de l\u2019Assurance Maladie pour 2016. Rapport au ministre charg\u00e9 de la S\u00e9curit\u00e9 sociale et au Parlement sur l\u2019\u00e9volution des charges et des produits de l\u2019Assurance Maladie au titre de 2016 (loi du 13 ao\u00fbt 2004). 2015. http:\/\/www.ameli.fr\/l-assurance-maladie\/statistiques-et-publications\/rapports-et-periodiques\/rapports-charges-produits-de-l-assurance-maladie\/rapports-charges-et-produits-pour-2013-a-2017\/rapport-charges-et-produits-pour-l-annee-2016.php . Accessed 27 Aug 2017."},{"key":"311_CR26","unstructured":"Sicart D. Les m\u00e9decins au 1er janvier 2013, Document de travail, S\u00e9rie statistiques, no 179, Drees, avril. 2013. http:\/\/drees.social-sante.gouv.fr\/etudes-et-statistiques\/publications\/documents-de-travail\/serie-statistiques\/article\/les-medecins-au-1er-janvier-2013 . Accessed 27 Aug 2017."},{"key":"311_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.4158\/EP15693.CS","volume":"21","author":"AJ Garber","year":"2015","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE\/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438\u201347.","journal-title":"Endocr Pract."},{"issue":"Suppl 1","key":"311_CR28","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.2337\/dc15-S010","volume":"38","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. Approaches to diabetes treatment. Diabetes Care. 2015;38(Suppl 1):S41\u20138.","journal-title":"Diabetes Care"},{"key":"311_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/VHRM.S75215","volume":"11","author":"PP Toth","year":"2014","unstructured":"Toth PP. Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vasc Health Risk Manag. 2014;11:9\u201323.","journal-title":"Vasc Health Risk Manag"},{"key":"311_CR30","unstructured":"HAS ANSM Recommandation de bonne pratique. Strat\u00e9gie m\u00e9dicamenteuse du contr\u00f4le glyc\u00e9mique du diab\u00e8te de type 2. 2013. http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2013-02\/10irp04_reco_diabete_type_2.pdf . Accessed 26 Aug 2017."},{"key":"311_CR31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s12325-015-0262-9","volume":"32","author":"R Jain","year":"2015","unstructured":"Jain R. Utility of saxagliptin in the treatment of type 2 diabetes: review of efficacy and safety. Adv Ther. 2015;32:1065\u201384.","journal-title":"Adv Ther."},{"key":"311_CR32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"311_CR33","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.lpm.2013.02.312","volume":"42","author":"C Druet","year":"2013","unstructured":"Druet C, Bourdel-Marchasson I, Weill A, et al. Type 2 diabetes in France: epidemiology, trends of medical care, social and economic burden. Presse Med. 2013;42:830\u20138.","journal-title":"Presse Med"},{"key":"311_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.diabet.2014.11.007","volume":"41","author":"E Eschwege","year":"2015","unstructured":"Eschwege E, Basdevant A, Crine A, et al. Type 2 diabetes mellitus in France in 2012: results from the ObEpi survey. Diabetes Metab. 2015;41:55\u201361.","journal-title":"Diabetes Metab."},{"key":"311_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13300-014-0064-0","volume":"5","author":"D Simon","year":"2014","unstructured":"Simon D, Detournay B, Eschwege E, et al. Use of vildagliptin in management of type 2 diabetes: effectiveness, treatment persistence and safety from the 2-year real-life VILDA study. Diabetes Ther. 2014;5:207\u201324.","journal-title":"Diabetes Ther."},{"key":"311_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.diabet.2015.03.007","volume":"41","author":"P Valensi","year":"2015","unstructured":"Valensi P, de Pouvourville G, Benard N, et al. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: the ODYSSEE observational study. Diabetes Metab. 2015;41:231\u20138.","journal-title":"Diabetes Metab."},{"key":"311_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.298.2.194","volume":"298","author":"RE Amori","year":"2007","unstructured":"Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194\u2013206.","journal-title":"JAMA"},{"key":"311_CR38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.18553\/jmcp.2014.20.2.120","volume":"20","author":"JA Davidson","year":"2014","unstructured":"Davidson JA. Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. J Manag Care Pharm. 2014;20:120\u20139.","journal-title":"J Manag Care Pharm."},{"key":"311_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4158\/EP161471.RA","volume":"23","author":"RY Gianchandani","year":"2017","unstructured":"Gianchandani RY, Neupane S, Iyengar JJ, Heung M. Pathophysiology and management of hypoglycemia in end-stage renal disease patients: a review. Endocr Pract. 2017;23:353\u201362.","journal-title":"Endocr Pract."},{"key":"311_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1053\/j.ajkd.2016.06.014","volume":"68","author":"PM Howse","year":"2016","unstructured":"Howse PM, Chibrikova LN, Twells LK, Barrett BJ, Gamble JM. Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2016;68:733\u201342.","journal-title":"Am J Kidney Dis"},{"key":"311_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s13300-016-0189-4","volume":"7","author":"MC Thomas","year":"2016","unstructured":"Thomas MC, Pald\u00e1nius PM, Ayyagari R, Ong SH, Groop PH. Systematic literature review of DPP-4 inhibitors in patients with type 2 diabetes mellitus and renal impairment. Diabetes Ther. 2016;7:439\u201354.","journal-title":"Diabetes Ther."},{"key":"311_CR42","first-page":"61","volume":"8","author":"M Davies","year":"2016","unstructured":"Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016;8:61\u201381.","journal-title":"Clin Pharmacol."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-017-0311-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13300-017-0311-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-017-0311-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T09:59:29Z","timestamp":1659520769000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13300-017-0311-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1007\/s13300-017-0311-2","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2017,9,25]]},"assertion":[{"value":"3 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}